查看購物車
  • Simplified Chinese
  • English
  • Japanese
美國前列腺癌檢測市場：國家分析：按生物標記類型、按癌症類型、按應用、按最終用戶、按地區 - 分析和預測（2025-2035 年）
市場調查報告書
商品編碼
1711584

美國前列腺癌檢測市場：國家分析：按生物標記類型、按癌症類型、按應用、按最終用戶、按地區 - 分析和預測（2025-2035 年）

U.S. Prostate Cancer Testing Market - A Country Analysis: Focus on Type of Biomarker, Cancer Type, Application, End User, and Region - Analysis and Forecast, 2025-2035
出版日期: | 出版商: BIS Research | 英文 120 Pages | 商品交期: 1-5個工作天內

價格

預計美國前列腺癌檢測市場的成長將受到癌症研究領域的大量投資和美國前列腺癌盛行率上升的推動。

此外，企業領導者的重點是透過深入了解美國前列腺癌檢測市場來滿足臨床研究中未滿足的需求。

美國前列腺癌檢測市場正處於發展階段。近幾十年來，對一般人群進行 PSA篩檢或檢測增加了前列腺癌的發生率。前列腺癌檢測對於精準醫療也至關重要，以確保安全和成功的個人化治療。美國前列腺癌檢測市場的大多數公司提供基於尿液、血液或組織的生物標記檢測或檢測服務。此外，前列腺癌檢測的應用主要在臨床和研究方面。

未來幾年美國前列腺癌檢測市場將擴大的主要原因之一是前列腺癌患者數量的增加。前列腺癌是男性第二大常見疾病，其發生率在全球範圍內呈上升趨勢。據估計，全球每年新增前列腺癌病例一百萬例。由於人口老化、都市化加快以及相關的生活方式改變，過去幾十年來前列腺癌的總體發病率有所增加。

根據生物標記類型，美國前列腺癌檢測市場的切片檢查前測試預計將由生物標記類型部分主導。這是由於前列腺癌檢測日益普及以及人們對前列腺癌檢測相關知識的認知不斷提高。

根據癌症類型，前列腺腺癌占美國前列腺癌檢測市場的最大佔有率。這是由於前列腺癌發生率不斷上升以及前列腺癌檢測日益普及。

從應用角度來看，美國前列腺癌檢測市場以診斷生物標記領域為主，這得益於專注於前列腺癌檢測開發的研究和開發活動不斷增加。正在開發新的基於分子的診斷技術來診斷前列腺癌。在診斷時檢測臨床相關的癌症需要多種工具和治療方案來改善患者的生活品質。

從最終用戶來看，美國前列腺癌檢測市場以門診手術中心（ASC）為主，這得益於 ASC 數量的不斷成長。 ASC 致力於提供當日手術護理，包括測試和保護程序。 ASC 在提供高品質護理和成功的患者治療結果方面有著良好的記錄，並透過為患者提供醫院門診手術的便利選擇，改變了數百萬美國人的門診體驗。

美國前列腺癌篩檢市場的最新趨勢

  • 2022 年 9 月，Veracyte 公司在《美國國家癌症研究所雜誌》上發表的數據顯示，該公司的解密前列腺基因資料可能有助於識別患有早期局限性前列腺癌且更有可能持有更具侵襲性的疾病的非裔美國男性。
  • 2019 年 8 月，BioReference Laboratories, Inc. 宣布已被美國 IPA 協會 (TIPAAA) 選為實驗室服務提供者，協助分析會員的病患資料。該協議旨在加強患者照護並為代表 39 個州的 667 多個醫療保健組織的 TIPAAA 成員提供協作健康管理工具。 TIPAAA 會員可以輕鬆存取 BioReference 的綜合測試菜單，包括常規和專科測試以及用於檢測進行性前列腺癌的 4Kscore。
  • 2021 年 6 月，賽默飛世爾科技宣布現正接受 Oncomine 臨床研究津貼計畫的申請，該計畫旨在支持腫瘤學臨床研究計劃。這項津貼旨在資助高品質的分子分析研究，並著重於免疫療法對癌症患者的影響。

工作流程/創新策略：工作流程部分幫助讀者了解兩種前列腺癌測試，即初步評估：前列腺特異性抗原（總 PSA、遊離 PSA）、切片檢查前/切片檢查後陰性測試和切片檢查後組織測試，進一步幫助診斷。此外，本研究也讓讀者詳細了解前列腺癌檢測在臨床和研究應用上的各種應用。

成長/行銷策略：前列腺癌檢測用於研究和臨床應用。各公司提供尿液、血液和組織生物標記來輔助診斷，這也是美國前列腺癌檢測市場參與企業在當前美國前列腺癌檢測市場中取得優勢的關鍵策略。

競爭策略：該研究分析並概述了美國前列腺癌檢測市場的主要企業，包括參與新產品發布、收購、業務擴展和策略聯盟的製造商。此外，對美國前列腺癌檢測市場新參與企業的詳細競爭基準化分析有助於讀者了解清晰的市場格局，並了解參與企業之間的競爭情況。此外，合作夥伴關係、協議和合作等全面的競爭策略可幫助讀者了解美國前列腺癌市場中尚未開發的收益來源。

主要市場參與企業和競爭對手的摘要

一波新的前列腺癌 (PCa) 生物標記正在出現，其 PCa 特異性高於 PSA 及其異構體，可增強 PCa篩檢技術。生物標記是一種分子，它的檢測或評估可以揭示超出傳統臨床特徵的疾病細節。生物標記存在於各種地方，包括血液、尿液和組織樣本。生物標記可以提供診斷和預後資料，幫助醫療保健專業人員預測疾病，從而為個別治療選擇提供資訊。美國前列腺癌檢測市場（按生物標記類型）不包括 PSA 檢測，分為切片檢查前/切片檢查後陰性檢測和切片檢查後組織檢測。

本報告研究了美國前列腺癌檢測市場，並概述了市場趨勢、生物標記類型、癌症類型、應用、最終用戶和地區，以及參與市場的公司概況。

目錄

執行摘要

第1章 市場概述

  • 市場足跡和成長潛力
  • 未來的可能性
  • 前列腺癌檢測的演變
  • 美國前列腺癌流行病學

第2章產業分析

  • 概述
  • 美國法律要求與框架
  • 專利分析
  • 生物標記在前列腺癌治療中的作用

第3章 市場動態

  • 概述
    • 影響分析
  • 市場促進因素
  • 市場限制
  • 市場機會

第4章美國前列腺癌檢測市場：競爭格局

  • 概述
  • 企業策略
    • 合併與收購
    • 協同效應活動
    • 業務擴展和資金籌措
  • 商務策略
    • 產品發布和核准
    • 出版品
    • 許可和協議
    • 其他活動
  • 美國報銷情況

第5章 美國前列腺癌檢測市場（按生物標記類型分類，單位：百萬美元），2023 年至 2035 年

  • 概述
  • 初步評估：前列腺特異性抗原（總PSA、遊離PSA）
  • 切片檢查前/活體組織切片後切片檢查檢測
    • 血液中的生物標記
    • 尿液生物標記
    • 影像學診斷
  • 切片檢查後的組織檢查
  • 切片檢查後檢查

第6章 美國前列腺癌檢測市場（按癌症類型分類，單位：百萬美元），2023 年至 2035 年

  • 概述
  • 攝護腺腺癌
  • 小細胞癌
  • 其他

第7章 美國前列腺癌檢測市場，按應用分類，（百萬美元），2023-2035

  • 概述
  • 臨床診斷生物標記
  • 預後生物標記（Prolaris、OncotypeDx、Decipher 等）

第 8 章 美國前列腺癌檢測市場，按最終用戶分類，（百萬美元），2023 年至 2035 年

  • 概述
  • 癌症研究所
  • 診斷實驗室
  • 醫院和診所
  • 門診手術中心（ASC）
  • 其他

第9章 美國前列腺癌檢測市場（按地區分類，單位：百萬美元），2023-2035

  • 概述
  • 美國東北部
  • 美國中西部
  • 美國南部
  • 美國西部

第10章 公司簡介

  • Abbott
  • Abcam plc.
  • Agilent Technologies, Inc.
  • Bio-Techne.（ExoDx）
  • Cleveland Diagnostics, Inc.
  • Danaher.（Beckman Coulter, Inc.）
  • Exact Sciences Corporation
  • F. Hoffmann-La Roche Ltd（FOUNDATION MEDICINE, INC.）
  • HU Group Holdings, Inc.（Fujeribio）
  • Mdxhealth
  • Siemens Healthcare GmbH
  • Myriad Genetics, Inc.
  • NeoGenomics Laboratories
  • OPKO Health, Inc.（GenPath）
  • Veracyte, Inc.
Product Code: BHP1297SB

U.S. Prostate Cancer Testing Market Industry Overview

The growth in the U.S. prostate cancer testing market is expected to be driven by high investments in the field of cancer research and the rising prevalence of prostate cancer in the U.S. In addition, the focus of business leaders is establishing a deep understanding to address the unmet needs in clinical research to understand the U.S. prostate cancer testing market.

Market Lifecycle Stage

The U.S. prostate cancer testing market is in the progressing phase. PSA screening or testing in a general population has increased the incidence of prostate cancer in recent decades. In addition, prostate cancer testing is essential in precision medicine because it assures the safe and successful use of tailored therapies. The majority of the companies in the U.S. prostate cancer testing market provide biomarker tests that are urine, blood, and tissue-based, as well as testing services. Furthermore, applications of prostate cancer testing are primarily clinical and research.

Impact

One of the main reasons for the expansion of the U.S. prostate cancer testing market in the upcoming years is the rise in prostate cancer cases. Prostate cancer is the second most frequent disease diagnosed in men, and its frequency is rising across the globe. Prostate cancer is thought to be diagnosed in one million additional cases worldwide each year. Due to an aging population, growing urbanization, and accompanying lifestyle changes, the overall incidence of prostate cancer has increased over the past few decades.

Market Segmentation:

Segmentation 1: by Biomarker Type

  • Initial Evaluation: Prostate-Specific Antigen (Total PSA, Free PSA)
  • Pre-Biopsy/Post-Negative Biopsy Testing
  • Post-Biopsy Tissue Testing

Based on biomarker type, the pre-biopsy test in the U.S. prostate cancer testing market is expected to be dominated by the biomarker type segment. This is due to the increasing popularity of prostate cancer testing and rising awareness related to prostate cancer testing.

Segmentation 2: by Cancer Type

  • Prostatic Adenocarcinoma
  • Small Cell Carcinoma
  • Other Prostate Cancer Types

Based on Cancer type, prostatic adenocarcinoma accounted for the largest share of the U.S. prostate cancer testing market. This is due to the increasing incidences of prostate cancer and increasing popularity of prostate cancer testing.

Segmentation 3: by Application

  • Diagnostics Biomarkers
  • Prognostics Biomarkers

Based on application, the U.S. prostate cancer testing market is dominated by the diagnostics biomarkers segment owing to the rising R&D activity focused on the development of prostate cancer testing. The diagnosis of prostate cancer has developed a new molecular-based diagnostics technology. To detect clinically relevant cancer upon diagnosis, several tools or therapeutic options are required to improve the patient's quality of life.

Segmentation 4: by End User

  • Cancer Research Institutes
  • Diagnostic Laboratories
  • Hospitals and Clinics
  • Ambulatory Surgical Centers (ASCs)
  • Others

Based on end user, the U.S. prostate cancer testing market is dominated by the ambulatory surgical centers (ASCs) segment owing to their rise in number. They are dedicated to offering same-day surgical care, including testing and protective procedures. ASCs, which have a proven track record of providing high-quality treatment and successful patient outcomes, have altered the outpatient experience for millions of Americans by giving patients a more convenient option for hospital-based outpatient operations.

Segmentation 5: by Region

  • Northeast U.S.
  • Midwest U.S
  • South U.S.
  • West U.S.

Recent Developments in the U.S. Prostate Cancer Testing Market

  • In September 2022, Veracyte, Inc. announced the publishing of data in the Journal of the National Cancer Institute to demonstrate the company's decipher prostate genomic classifier may help identify African American men with early, localized prostate cancer who are most likely to harbor more aggressive disease.
  • In August 2019, BioReference Laboratories, Inc. announced the selection by The IPA Association of America (TIPAAA) as its provider of laboratory services and to assist with data analytics for its members' patients. The agreement is designed to enhance patient care and offers collaborative health management tools to TIPAAA members, which includes more than 667 medical organizations in 39 states. The members can have convenient access to BioReference's comprehensive laboratory testing menu, including routine and specialty tests, as well as the 4Kscore for detecting aggressive prostate cancer.
  • In June 2021, Thermo Fisher Scientific announced submissions open for the Oncomine Clinical Research Grant program to support clinical research projects in oncology. The grant aims to provide funding for high-quality molecular profiling studies focusing on the impact of immune-based treatments for cancer patients.

Demand - Drivers and Limitations

The following are the demand drivers for the U.S. prostate cancer testing market:

  • Rising prevalence of prostate cancer in the U.S.
  • Increasing number of prostate cancer screening and testing
  • Government initiatives related to prostate cancer

The market is expected to face some limitations due to the following challenges:

  • High Probability of false positive results of prostate cancer testing
  • Clinical gaps related to prostate cancer testing

How can this report add value to an organization?

Workflow/Innovation Strategy: The workflow segment helps the reader understand the two prostate cancer testing, i.e., initial evaluation: prostate-specific antigen (total PSA, free PSA), pre-biopsy/post-negative biopsy testing, and post-biopsy tissue testing, which further aid in diagnosis. Moreover, the study provides the reader with a detailed understanding of the different applications of prostate cancer testing in clinical and research applications.

Growth/Marketing Strategy: Prostate cancer testing is being used for both research and clinical application. Various companies are providing urine and blood, and tissue-based biomarkers that aid in the diagnosis, which is also the key strategy for U.S. prostate cancer testing market players to excel in the current U.S. prostate cancer testing market.

Competitive Strategy: Key players in the U.S. prostate cancer testing market are analyzed and profiled in the study, including manufacturers who are involved in new product launches, acquisitions, expansions, and strategic collaborations. Moreover, a detailed competitive benchmarking of the players operating in the U.S. prostate cancer testing market has been done to help the reader understand how players stack against each other, presenting a clear market landscape. Additionally, comprehensive competitive strategies such as partnerships, agreements, and collaborations will aid the reader in understanding the untapped revenue pockets in the U.S. prostate cancer market.

Key Market Players and Competition Synopsis

A new wave of prostate cancer (PCa) biomarkers with greater PCa specificity than PSA and its isoforms have emerged to enhance PCa screening techniques. Biomarkers are molecules that, when detected or assessed, reveal details about a disease that goes beyond conventional clinical characteristics. They can be found in a number of places, including blood, urine, and tissue samples. Both diagnostic and prognostic data can be provided by biomarkers, supporting healthcare professionals in formulating illness projections intended to inform treatment choices on an individual basis. The U.S. prostate cancer testing market (by biomarker type) excluding PSA Tests is segmented into pre-biopsy/post-negative biopsy testing and post-biopsy tissue testing.

Some of the prominent names in the U.S. prostate cancer testing market are:

  • Danaher. (Beckman Coulter, Inc.)
  • Opko Health, Inc. (Genpath, Inc.)
  • Bio-Techne
  • Cleaveland Diagnostics, Inc.
  • mdxhealth
  • Myriad Genetics, Inc.
  • Exact Sciences Corporation
  • Veracyte, Inc.
  • mdxhealth

Companies that are not a part of the aforementioned pool have been well represented across different sections of the report (wherever applicable).

Table of Contents

Executive Summary

Scope and Definition

Market/Product Definition

Inclusion and Exclusion

Key Questions Answered

Analysis and Forecast Note

Research Methodology

1. Markets Overview

  • 1.1 Market Footprint and Growth Potential
  • 1.2 Future Potential
  • 1.3 Evolution of Prostate Cancer Testing
  • 1.4 Epidemiology of Prostate Cancer in the U.S.
    • 1.4.1 Southern U.S.
    • 1.4.2 Midwest U.S.
    • 1.4.3 Mid-Atlantic U.S.
    • 1.4.4 West U.S.
    • 1.4.5 Southwest U.S.
    • 1.4.6 New England e

2. Industry Analysis

  • 2.1 Overview
  • 2.2 Legal Requirements and Framework in the U.S
    • 2.2.1 National Comprehensive Cancer Network (NCCN) Guidelines
    • 2.2.2 American Urological Association (AUA)
    • 2.2.3 American Cancer Society (ACS)
    • 2.2.4 U.S. Preventive Services Task Force (USPSTF)
  • 2.3 Patent Analysis
    • 2.3.1 Patent Filing Trend
  • 2.4 Role of Biomarkers in Prostate Cancer Management

3. Market Dynamics

  • 3.1 Overview
    • 3.1.1 Impact Analysis
  • 3.2 Market Drivers
  • 3.3 Market Restraints
  • 3.4 Market Opportunities

4. U.S. Prostate Cancer Testing Market: Competitive Landscape

  • 4.1 Overview
  • 4.2 Corporate Strategies
    • 4.2.1 Mergers and Acquisitions
    • 4.2.2 Synergistic Activities
    • 4.2.3 Business Expansions and Funding
  • 4.3 Business Strategies
    • 4.3.1 Product Launches and Approvals
    • 4.3.2 Publications
    • 4.3.3 Licenses and Agreements
    • 4.3.4 Other Activities
  • 4.4 Reimbursement Scenario in the U.S.

5. U.S. Prostate Cancer Testing Market (by Biomarker Type), ($Million), 2023-2035

  • 5.1 Overview
  • 5.2 Initial Evaluation: Prostate-Specific Antigen (Total PSA, Free PSA)
  • 5.3 Pre-Biopsy/Post-Negative Biopsy Testing
    • 5.3.1 Blood-Based Biomarker
    • 5.3.2 Urine-Based Biomarker
    • 5.3.3 Imaging
      • 5.3.3.1 Multiparametric Magnetic Resonance Imaging (mp-MRI)
  • 5.4 Post-Biopsy Tissue Testing
  • 5.5 Post-Biopsy Test

6. U.S. Prostate Cancer Testing Market (by Cancer Type), ($Million), 2023-2035

  • 6.1 Overview
  • 6.2 Prostatic Adenocarcinoma
  • 6.3 Small Cell Carcinoma
  • 6.4 Other Prostate Cancer Type

7. U.S. Prostate Cancer Testing Market (by Application), ($Million), 2023-2035

  • 7.1 Overview
  • 7.2 Clinical Diagnostic Biomarkers
  • 7.3 Prognostic Biomarkers (Prolaris, OncotypeDx, Decipher, etc.)

8. U.S. Prostate Cancer Testing Market (by End User), ($Million), 2023-2035

  • 8.1 Overview
  • 8.2 Cancer Research Institutes
  • 8.3 Diagnostic Laboratories
  • 8.4 Hospitals and Clinics
  • 8.5 Ambulatory Surgical Centers (ASCs)
  • 8.6 Others

9. U.S. Prostate Cancer Testing Market (by Region), ($Million), 2023-2035

  • 9.1 Overview
  • 9.2 Northeast U.S.
    • 9.2.1 Northeast U.S. (Prostate-Specific Antigen (PSA)
    • 9.2.2 Northeast U.S. (Pre-Biopsy/Post-Negative Biopsy Testing)
    • 9.2.3 Northeast U.S. (Post-Biopsy Tissue Testing)
  • 9.3 Midwest U.S.
    • 9.3.1 Midwest U.S. (Prostate-Specific Antigen (PSA)
    • 9.3.2 Midwest U.S. (Pre-Biopsy/Post-Negative Biopsy Testing)
    • 9.3.3 Midwest U.S. (Post-Biopsy Tissue Testing)
  • 9.4 South U.S.
    • 9.4.1 South U.S. (Prostate-Specific Antigen (PSA)
    • 9.4.2 South U.S. (Pre-Biopsy/Post-Negative Biopsy Testing)
    • 9.4.3 South U.S. (Post-Biopsy Tissue Testing)
  • 9.5 West U.S.
    • 9.5.1 West U.S. (Prostate-Specific Antigen (PSA)
    • 9.5.2 West U.S. (Pre-Biopsy/Post-Negative Biopsy Testing)
    • 9.5.3 West U.S. (Post-Biopsy Tissue Testing)

10. Company Profiles

  • 10.1 Abbott
    • 10.1.1 Overview
    • 10.1.2 Top Products / Product Portfolio
    • 10.1.3 Top Competitors
    • 10.1.4 Target Customers/End-Users
    • 10.1.5 Key Personnel
    • 10.1.6 Analyst View
  • 10.2 Abcam plc.
    • 10.2.1 Overview
    • 10.2.2 Top Products / Product Portfolio
    • 10.2.3 Top Competitors
    • 10.2.4 Target Customers/End-Users
    • 10.2.5 Key Personnel
    • 10.2.6 Analyst View
  • 10.3 Agilent Technologies, Inc.
    • 10.3.1 Overview
    • 10.3.2 Top Products / Product Portfolio
    • 10.3.3 Top Competitors
    • 10.3.4 Target Customers/End-Users
    • 10.3.5 Key Personnel
    • 10.3.6 Analyst View
  • 10.4 Bio-Techne. (ExoDx)
    • 10.4.1 Overview
    • 10.4.2 Top Products / Product Portfolio
    • 10.4.3 Top Competitors
    • 10.4.4 Target Customers/End-Users
    • 10.4.5 Key Personnel
    • 10.4.6 Analyst View
  • 10.5 Cleveland Diagnostics, Inc.
    • 10.5.1 Overview
    • 10.5.2 Top Products / Product Portfolio
    • 10.5.3 Top Competitors
    • 10.5.4 Target Customers/End-Users
    • 10.5.5 Key Personnel
    • 10.5.6 Analyst View
  • 10.6 Danaher. (Beckman Coulter, Inc.)
    • 10.6.1 Overview
    • 10.6.2 Top Products / Product Portfolio
    • 10.6.3 Top Competitors
    • 10.6.4 Target Customers/End-Users
    • 10.6.5 Key Personnel
    • 10.6.6 Analyst View
  • 10.7 Exact Sciences Corporation
    • 10.7.1 Overview
    • 10.7.2 Top Products / Product Portfolio
    • 10.7.3 Top Competitors
    • 10.7.4 Target Customers/End-Users
    • 10.7.5 Key Personnel
    • 10.7.6 Analyst View
  • 10.8 F. Hoffmann-La Roche Ltd (FOUNDATION MEDICINE, INC.)
    • 10.8.1 Overview
    • 10.8.2 Top Products / Product Portfolio
    • 10.8.3 Top Competitors
    • 10.8.4 Target Customers/End-Users
    • 10.8.5 Key Personnel
    • 10.8.6 Analyst View
  • 10.9 H.U. Group Holdings, Inc. (Fujeribio)
    • 10.9.1 Overview
    • 10.9.2 Top Products / Product Portfolio
    • 10.9.3 Top Competitors
    • 10.9.4 Target Customers/End-Users
    • 10.9.5 Key Personnel
    • 10.9.6 Analyst View
  • 10.10 Mdxhealth
    • 10.10.1 Overview
    • 10.10.2 Top Products / Product Portfolio
    • 10.10.3 Top Competitors
    • 10.10.4 Target Customers/End-Users
    • 10.10.5 Key Personnel
    • 10.10.6 Analyst View
  • 10.11 Siemens Healthcare GmbH
    • 10.11.1 Overview
    • 10.11.2 Top Products / Product Portfolio
    • 10.11.3 Top Competitors
    • 10.11.4 Target Customers/End-Users
    • 10.11.5 Key Personnel
    • 10.11.6 Analyst View
  • 10.12 Myriad Genetics, Inc.
    • 10.12.1 Overview
    • 10.12.2 Top Products / Product Portfolio
    • 10.12.3 Top Competitors
    • 10.12.4 Target Customers/End-Users
    • 10.12.5 Key Personnel
    • 10.12.6 Analyst View
  • 10.13 NeoGenomics Laboratories
    • 10.13.1 Overview
    • 10.13.2 Top Products / Product Portfolio
    • 10.13.3 Top Competitors
    • 10.13.4 Target Customers/End-Users
    • 10.13.5 Key Personnel
    • 10.13.6 Analyst View
  • 10.14 OPKO Health, Inc. (GenPath)
    • 10.14.1 Overview
    • 10.14.2 Top Products / Product Portfolio
    • 10.14.3 Top Competitors
    • 10.14.4 Target Customers/End-Users
    • 10.14.5 Key Personnel
    • 10.14.6 Analyst View
  • 10.15 Veracyte, Inc.
    • 10.15.1 Overview
    • 10.15.2 Top Products / Product Portfolio
    • 10.15.3 Top Competitors
    • 10.15.4 Target Customers/End-Users
    • 10.15.5 Key Personnel
    • 10.15.6 Analyst View

List of Figures

  • Figure: U.S. Prostate Cancer Testing Market, Dynamics Impact Analysis
  • Figure: U.S.Prostate Cancer Testing Market Coverage
  • Figure: U.S.Prostate Cancer Testing Market Key Trends, Impact Analysis, 2023-2035
  • Figure: U.S.Prostate Cancer Testing Market, Patent Analysis, January 2022-March 2025

List of Tables

  • Table: U.S. Prostate Cancer Testing Market, Patent Analysis, January 2022-March 2025
  • Table: U.S.Prostate Cancer Testing Market Dynamics, Impact Analysis
  • Table: U.S.Prostate Cancer Testing Market (by Biomarker Type), $Million, 2023-2035
  • Table: U.S.Prostate Cancer Testing Market (by Cancer Type), $Million, 2023-2035
  • Table: U.S.Prostate Cancer Testing Market (by Application), $Million, 2023-2035
  • Table: U.S. Prostate Cancer Testing Market (by End User), $Million, 2023-2035
  • Table: U.S. Prostate Cancer Testing Market (by Region), $Million, 2023-2035